http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-4205938-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f06faeb9c558d826cf1f19ce4103d13 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate | 1992-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0d4e3425b1cf6850d51acc6de6709bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b7fce8139032db364190d78dca6e736 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58b25fa137feb8f19f3628d6a25ee6f6 |
| publicationDate | 1993-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-4205938-A1 |
| titleOfInvention | IMMUNOTOXINE |
| abstract | New immunotoxin (I) comprises monoclonal CD30 antibodies (Ab) covalently bonded to a ribosome-inactivating protein type-1 toxin (II). Pref. Ab is of the Ber-H2 type while (II) is bryodin; the toxin purified from Asparagus officinalis; momorcochin-5; dianthin; gelonin; trichosanthin or pref. saporin; PAP (from Phytolacca americana seeds) and/or momordin. Ab, esp. Ber-H2 from the hybridoma ECACC 92012823, and (II) are coupled using a heterobifunctional reagent, e.g. N-succininidyl-3-(2-pyridyldithio)propionate; S-acetyl-mercaptosuccinic anhydride; a carbodiimide; glutaraldehyde or esp. 2-iminothiolan (2-IT; sec Br. J cancer, 60 (1989) 315). Ab is isolated from hybridoma culture supernatant (or ascites) by affinity chromatography on protein A and then hydroxyapatite chromatography. It is derivatised with 2-IT in pH9 borate buffer then incubated for 20 hr at room temp. with 2-IT-derivatised toxin (reduced with dithiothreitol). The reaction mixt. was gel. filtered on 'Sephacryl S-200' (RTM) and the fractions contg. the low molecular wt. conjugate isolated (esp. it has mole ratio (II): Ab = 1-3). USE/ADVANTAGE - (I) can be used (1) for treating tumours and (2) for selective elimination, in vivo or ex vivo, of CD-30 positive cells. They are more active than similar immuno toxins prepd. from ricin A chain and give partic. good results in cases of Hodgkin's disease. (I) is administered by intramuscular or intravenous injection (as a soln. or suspension) to provide a dose of 0.01-5 (pref. 0.01-0.5) mg/kg, given one or more times per day for one to several weeks. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9717374-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9640260-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1463942-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1463942-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9622384-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019166932-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6033876-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9640260-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6071519-A |
| priorityDate | 1992-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.